Video Experimental Relacionado
Updated: Jan 8, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Edaravona Modula la Expresión de Componentes de la Inflamación NLRP3 y Atenúa las Alteraciones Morfológicas de las
Marco A Noriega-Ruiz1, Tania Covarrubias-Navarro1, Laura Medina-Ceja2
1Department of Cellular and Molecular Biology, Laboratory of Neurophysiology, University of Guadalajara, Zapopan, Jalisco, Mexico.
Abstract:
After a status epilepticus (SE) event, the NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome is activated, accompanied by morphological alterations in microglia and astrocytes, which are key features of inflammation. Antioxidants have been shown to inhibit NLRP3 inflammasome activation and suppress glial cell morphological alterations. In this study, firstly we evaluated the antiseizure effect of the antioxidant edaravone (EDA) at different doses on the convulsive behavior and epileptiform activity induced by pilocarpine (Pilo) in order to determine the most appropriate dose for subsequent experiments. Later, for the main study, we investigated the temporal expression of NLRP3 inflammasome components and glial cell morphological characteristics following SE to assess the efficacy of the EDA, using a rat model of SE induced by Pilo and conducted a temporal analysis of the protein expression of NLRP3, IL-1β, caspase-1 p20 and IL-10 by nano dot blotting. Additionally, Sholl analysis was performed to evaluate glial cell morphology. Our findings revealed an increase in the expression of NLRP3 inflammasome components after SE, accompanied by glial cell morphological changes characteristic of a reactive state. Furthermore, EDA significantly reduced NLRP3 expression, decreased IL-10 levels and mitigated SE-induced morphological alterations in glial cells.
Videos de Conceptos Relacionados
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists

